Industry Briefs: October 22, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: October 22, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

AMRI has extended its API supply agreement with Shire. Read More

Aptuit has announced the offering of antibacterial studies from a single site, the Aptuit Center for Drug Discovery & Development in Verona, Italy.

The National Institute of Allergy and Infectious Diseases has awarded Pfenex a contract to develop an alternative delivery method for its recombinant protective antigen (rPA)-based anthrax vaccine. Read More

Pluristem Therapeutics has achieved a milestone towards the completion of its new GMP manufacturing facility for commercial production of the company’s Placental eXpanded cells. Read More

The United States Pharmacopeial Convention (USP) has selected the Thermo Scientific TruScan RM and microPHAZIR RX instruments to support its recent initiative to provide USP-approved spectral libraries to pharmaceutical manufacturers. Read More

People News

AMRI has appointed Steven R. Hagen as senior vice-president of pharmaceutical development and manufacturing. Read More

Cobra Biologics has appointed John Birch, former chief scientific officer for Lonza Biopharmaceuticals, as a nonexecutive director. Read More

ISPE has announced its 2012–2013 board of directors election results, including Charlotte Enghave Fruergaard as chair and Damian Greene as vice-chair. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here